Clinical and experimental psychology最新文献

{"title":"Evidence for the <i>DRD2</i> Gene as a Determinant of Reward Deficiency Syndrome (RDS).","authors":"Kenneth Blum,&nbsp;Abdala Bowirrat,&nbsp;Igor Elman,&nbsp;David Baron,&nbsp;Panayotis K Thanos,&nbsp;Mark S Gold,&nbsp;Colin Hanna,&nbsp;Milan T Makale,&nbsp;Keerthy Sunder,&nbsp;Nicole Jafari,&nbsp;Foojan Zeine,&nbsp;Kevin T Murphy,&nbsp;Miles Makale,&nbsp;Rajendra D Badgaiyan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Since 1990, published addiction psychiatry articles have exceeded 11,495. Several from Blum et al. showed the clinical relevance of the Genetic Addiction Risk Severity (GARS) test in identifying risk for reward deficiency behaviors in cohorts from polysubstance and pain clinics, post-surgical bariatrics, and DWI offenders facing prison time. Since Blum <i>et al</i> first published in JAMA (1990) concerning the association of the <i>DRD2</i> gene polymorphism and severe alcoholism, confirmation has been mixed and controversial. More recently, however, a meta-analysis of 62 studies showed a significant association between <i>DRD2</i> rs 1800497 and Alcohol Use Disorder (AUD). Other studies from Yale University showed that a haplotype block of the <i>DRD2</i> gene A1 allele was associated with AUD and heroin dependence. GWAS studies of depression and suicide in 1.2 million veterans confirmed the first psychiatric candidate gene study finding from Blum et al. 1990; a significant association between the minor <i>DRD2</i> allele, Taq A1 (rs 1800497 C>T) and severe alcoholism. Additionally, the <i>DRD2</i> rs1800497 is associated with suicide behaviors robustly at P=1.77 × 10^-7. Furthermore, DNA polymorphic alleles underlying SUD with multiple substances were mapped via chromatin refolding, revealed that the <i>DRD2</i> gene and associated polymorphism(s) was the top gene signal (DRD2, P=7.9 × 10^-12). Additionally, based on these investigations, we conclude that GWAS should end the controversy about the <i>DRD2</i> gene being at least one determinant of Reward Deficiency Syndrome (RDS) first reported in the Royal Society of Medicine journaling 1996.</p>","PeriodicalId":72603,"journal":{"name":"Clinical and experimental psychology","volume":"9 4","pages":"8-11"},"PeriodicalIF":0.0,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9996638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?","authors":"Kenneth Blum, Abdalla Bowirrat, Eric R Braverman, Catherine Dennen, Foojan Zeine, Nicole Jafari, Keerthy Sunder, Panayotis K Thanos, David Baron, Debmayla Barh, Ashim Gupta, Debasis Bagchi, Mark S Gold, Rajendra D Badgaiyan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>One important area for consideration especially in terms of combating the ongoing never ending opioid crisis, relates to novel newer assessments for all addictive behaviors both substance and non-substance behaviors (RDS). It is very important to identify early in one's life the possibility of, because of known DNA antecedents, the presence of pre-addiction. The development of the Genetic Addiction Risk Severity (GARS) test, Blum's group believes that this type of testing should be the \"standard of care\" following additional studies. Understandably that while polymorphisms in the Mu-Opioid receptor (MOR) is of real concern in terms of setting people up for predisposition to opioid dependence, the genetic and epigenetic status of dopaminergic function must be considered as well. While this sounds bold (which it is) the results should be protected by the G.I. N. A. law enacted in the USA in 2011. One avenue of further investigation, instead of providing powerful opioids for opioid dependence, is to seek out non-addictive alternatives. Accordingly, other non-addictive modalities including genetic guided KB220 (amino-acid-enkephalinase-N-acetylcysteine-NAD), non-invasive rTMS for psychiatry and pain, epigenetic remodeling, gene edits, non-invasive H-wave for pain management and enhanced functionality, brain spotting, cognitive behavioral therapy awarenesss integration therapy, NUCALM, trauma therapy, awareness tools, genograms, exercise, sports, fitness programs (one hour per day), light therapy and even laughing therapy as well as any other known modalities that can induce reward symmetry. While the short term use of opioids for opioid dependence to reduce harm is certainly acceptable, clinicians should consider a better long-term plan.</p>","PeriodicalId":72603,"journal":{"name":"Clinical and experimental psychology","volume":"9 2","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9717487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlapping Risky Decision-Making and Olfactory Processing Ability in HIV-Infected Individuals.","authors":"Christopher Jackson, Narayan Rai, Charlee K McLean, Maria Mananita S Hipolito, Flora Terrell Hamilton, Suad Kapetanovic, Evaristus A Nwulia","doi":"10.4172/2471-2701.1000160","DOIUrl":"10.4172/2471-2701.1000160","url":null,"abstract":"<p><strong>Objective: </strong>Given neuroimaging evidences of overlap in the circuitries for decision-making and olfactory processing, we examined the hypothesis that impairment in psychophysical tasks of olfaction would independently predict poor performances on Iowa Gambling Task (IGT), a laboratory task that closely mimics real-life decision-making, in a US cohort of HIV-infected (HIV+) individuals.</p><p><strong>Method: </strong>IGT and psychophysical tasks of olfaction were administered to a Washington DC-based cohort of largely African American HIV+ subjects (N=100), and to a small number of demographically-matched non-HIV healthy controls (N=43) from a different study. Constructs of olfactory ability and decision-making were examined through confirmatory factor analysis (CFA). Structural equation models (SEMs) were used to evaluate the validity of the path relationship between these two constructs.</p><p><strong>Result: </strong>The 100 HIV+ participants (56% female; 96% African Americans; median age = 48 years) had median CD4 count of 576 cells/μl and median HIV RNA viral load <48 copies per milliliter. Majority of HIV+ participants performed randomly throughout the course of IGT tasks, and failed to demonstrate a learning curve. Confirmatory factor analysis provided support for a unidimensional factor underlying poor performances on IGT. Nomological validity for correlations between olfactory ability and IGT performance was confirmed through SEM. Finally, factor scores of olfactory ability and IGT performance strongly predicted 6 months history of drug use, while olfaction additionally predicted hallucinogen use.</p><p><strong>Conclusion: </strong>This study suggests that combination of simple, office-based tasks of olfaction and decision-making may identify those HIV+ individuals who are more prone to risky decision-making. This finding may have significant clinical, public health value if joint impairments in olfaction and IGT task correlates with more decreased activity in brain regions relevant to decision-making.</p>","PeriodicalId":72603,"journal":{"name":"Clinical and experimental psychology","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648356/pdf/nihms902426.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35532461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apo E4 Alleles and Impaired Olfaction as Predictors of Alzheimer's Disease.","authors":"Magdalena M Misiak, MariaMananita S Hipolito, Habtom W Ressom, Thomas O Obisesan, Kebreten F Manaye, Evaristus A Nwulia","doi":"10.4172/2471-2701.1000169","DOIUrl":"10.4172/2471-2701.1000169","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is the most common form of dementia that affects more than 5 million Americans. It is the only disease among the 10 causes of death that cannot be slowed or cured, thus raising the need for identification of early preclinical markers that could be the focus of preventative efforts. Although evidence is escalating that abnormalities in olfactory structure and function precede AD development and early cognitive impairments by one or more decades, the importance of olfaction is largely overlooked in AD, and such testing is not routinely performed in neurology clinics. Nevertheless, research using the olfactory model, has begun to advance our understanding of the preclinical pathophysiology of AD. Notably, an interesting series of studies is beginning to illuminate the relationship between Apolipoprotein E (ApoE) ε4 polymorphism and olfactory dysfunction and late-onset Alzheimer's disease. In this article, we reviewed present research on the significance of ApoE and olfaction to AD, summarized current studies on the associations and mechanisms of ApoE and olfactory dysfunction, and highlighted important gaps for future work to further advance the translational application of the olfactory paradigm to early, preclinical diagnosis and treatment of AD.</p>","PeriodicalId":72603,"journal":{"name":"Clinical and experimental psychology","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/24/nihms936520.PMC5800509.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35813732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}